Clinical Trial Update: SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease. [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety, tolerability, pharmacokinetics and pharmacodynamics of MEDI1814 in mild-to-moderate Alzheimer's disease patients (completed; res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• MEDI1814

Snippet

Sponsor: AstraZeneca | Conditions: Mild-Moderate Alzheimer's Disease, Healthy Elderly | Phase 1 | Status: COMPLETED | Results posted: 2019-06-03